Orionpharma.no

Reference list - Simdax® (levosimendan) selection of publications
HEART FAILURE
Parissis J, Toller W, Franco F, et al.
Levosimendan: a decade of experience in Europe built
• GENERAL
on years of evidence. Eur J Heart Fail 2008;(Suppl 7);234­243.
Giglioli C, Cecchi E, Landi D, et al.
Levosimendan produces an additional clinical and hemo­
Mebazaa A. Nieminen MS, Packer M, et al.
dynamic benefit in patients with decompensated heart Levosimendan vs dobutamine for patients with acute failure successfully submitted to a fluid removal treatment. decompensated heart failure. The SURVIVE randomized Aidonidis G, Kanonidis I, Koutsimanis V, et al.
Efficiency and safety of prolonged levosimendan infusion in
Parissis JT, Papadopoulos C, Nikolaou M, et al.
Effects of levosimendan on quality of life and emotional Cardiol Res Pract 2011;Mar 31:342302.
stress in advanced heart failure patients. Cardiovasc Drugs Ther 2007;21:263­268.
Feola M, Lombardo E, Taglieri C, et al.
Effects of levosimendan/furosemide infusion on plasma
Adamopoulos S, Parissis JT, Iliodromitis EK, et al.
brain natriuretic peptide, echocardiographic parameters Effects of levosimendan versus dobutamine on inflamma­ and cardiac output in end­stage heart failure patients. tory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006;98:102­106.
Lunghetti S, Palmerini E, Urselli R, et al.
Effects of levosimendan without loading dose on systolic
Dernellis J, Panaretou M.
and diastolic function in patients with end­stage heart Effects of levosimendan on restrictive left ventricular filling in severe heart failure: A combined hemodynamic and Doppler echocardiograpic study. Chest 2005;128:2633­2639.
Bergh C-H, Andersson B, Dahlström U, et al.
Intravenous levosimendan vs. dobutamine in acute
Kivikko M, Lehtonen L, Colucci WS, et al.
decompensated heart failure patients on beta­blockers. Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003;107:81­86. Branzi G, Malfatto G, Villani A, et al.
Acute effects of levosimendan on mitral regurgitation
Follath F, Cleland JGF, Just H, et al.
and diastolic function in patients with advanced chronic Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low­output heart failure (the LIDO study): a randomised double­blind trial. Lancet 2002;360:196­202. Farmakis D, Parissis JT, Bistola V, et al.
Plasma B­type natriuretic peptide reduction predicts
Nieminen MS, Akkila J, Hasenfuss G, et al.
long­term response to levosimendan therapy in acutely Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1903­1912.
Kivikko M, Sundberg S, Karlsson MO, et al.
Acetylation status does not affect levosimendan’s
Slawsky MT, Colucci WS, Gottlieb SS, et al.
hemodynamic effects in heart failure patients. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000;102:2222­2227.
Cohen-Solal A, Logeart D, Huang B, et al.
Lowered B­type natriuretic peptide in response to levosi­
mendan or dobutamine treatment is associated with
• RIGHT VENTRICULAR FAILURE
improved survival in patients with severe acutely Russ MA, Prondzinsky R, Carter JM, et al.
Right ventricular function in myocardial infarction complica­ J Am Coll Cardiol 2009;53:2343­2348.
ted by cardiogenic shock: improvement with levosimendan. Mebazaa A, Nieminen MS, Filippatos GS, et al.
Levosimendan vs. dobutamine: outcomes for acute heart Yilmaz MB, Yontar C, Erdem A, et al.
failure patients on beta­blockers in SURVIVE. Comparative effects of levosimendan and dobutamine on right ventricular function in patients with biventricular Silva-Cardoso J, Ferreira J, Oliveira-Soares A, et al.
Effectiveness and safety of levosimendan in clinical practice. Duygu H, Ozerkan F, Zoghi M, et al.
De Santis V, Vitale D, Tritapepe L, et al.
Effect of levosimendan on right ventricular systolic and dias­ Use of levosimendan for cardiogenic shock in a patient with tolic functions in patients with ischaemic heart failure. Poelzl G, Zwick RH, Grander W, et al.
Yilmaz MB, Yalta K, Yontar C, et al.
Safety and effectiveness of levosimendan in patients with Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther 2007;21:431­435. Parissis JT, Paraskevaidis I, Bistola V, et al.
Effects of levosimendan on right ventricular function in
Zemljic G, Bunc M, Yazdanbakhsh AP, et al.
Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac trans­plantation. J Cardiac Fail 2007;13:417­421.
• INTERMITTENT ADMINISTRATION
Malfatto G, Della Rosa F, Villani A, et al.
Intermittent levosimendan infusions in advanced heart
CARDIAC SURGERY
failure: favourable effects on left ventricular function, Levin R, Degrange M, Del Mazo C, et al.
neurohormonal balance, and one­year survival. Preoperative levosimendan decreases mortality and the J Cardiovasc Pharmacol 2012;60:450­455.
development of low cardiac output in high­risk patients Papadopoulou P, Mavrogeni SI, Dritsas A, et al.
with severe left ventricular dysfunction undergoing Assessment of quality of life using three activity question­ coronary artery bypass grafting with cardiopulmonary naires in heart failure patients after monthly, intermittent administration of levosimendan during a six­month period. Hellenic J Cardiol 2009;50:269­274.
Sponga S, Ivanitskaia E, Potapov E, et al.
Parle NM, Thomas MD, Dembo L, et al.
Preoperative treatment with levosimendan in candidates for Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart Elahi MM, Lam J, Asopa S, et al.
Levosimendan versus an intra­aortic balloon pump in adult Mavrogeni S, Giamouzis F, Papadopoulou E, et al.
cardiac surgery patients with low cardiac output. A 6­month follow­up of intermittent levosimendan admi­ J Cardiothorac Vasc Anesth 2011;25:1154­1162.
nistration effect on systolic function, specific activity ques­ Lahtinen P, Pitkänen O, Pölönen P, et al.
tionnaire, and arrhythmia in advanced heart failure. Levosimendan reduces heart failure after cardiac surgery – a prospective, randomized, placebo­controlled trial. Parissis JT, Adamopoulos S, Farmakis D, et al.
Effects of serial levosimendan infusions on left ventricular Lomivorotov VV, Cherniavskiy AM, Boboshko VA, et al.
performance and plasma biomarkers of myocardial injury Levosimendan vs. intra­aortic balloon pump in high­risk and neurohormonal and immune activation in patients Asian Cardiovasc Thorac Ann 2011;19:154­159.
Brezina A, Riha H, Pirk J.
Nanas JN, Papazoglou P, Tsagalou EP, et al.
Prophylactic application of levosimendan in cardiac surgical Efficacy and safety of intermittent, long­term, concomitant patients with severe left ventricle dysfunction. dobutamine and levosimendan infusions in severe heart Eriksson HI, Jalonen JR, Heikkinen LO, et al.
Levosimendan facilitates weaning from cardiopulmonary Spargias KS, Anifantakis A, Papadakis M, et al.
bypass in patients undergoing coronary artery bypass Preliminary clinical experience with the repetitive admi­ grafting with impaired left ventricular function. nistration of levosimendan in patients with end­stage Salmenperä M, Eriksson H.
Ital Heart J 2003;4(Suppl 2):45S­49S.
Levosimendan in perioperative and critical care patients. Curr Opin Anaesthesiol 2009;22:496­501.
• RENAL FUNCTION
Tritapepe L, De Santis V, Vitale D, et al.
Zorlu A, Yücel H, Yontar OC, et al.
Levosimendan pre­treatment improves outcomes in patients Effect of levosimendan in patients with severe systolic heart undergoing coronary artery bypass graft surgery. Weis F, Beiras-Fernandez A, Kaczmarek I, et al.
Puttonen J, Kantele S, Kivikko M, et al.
Levosimendan: a new therapeutic option in the treatment Effect of severe renal failure and haemodialysis on the of primary graft dysfunction after heart transplantation. pharmacokinetics of levosimendan and its metabolites. J Heart Lung Transplant 2009;28:501­504.
Clin Pharmacokinet 2007;46:235­246.
Beiras-Fernandez A, Weis FC, Kur F, et al.
Buerke M, Lemm H, Krohe K, et al.
Primary graft failure and Ca2+ sensitizers after heart trans­ Levosimendan in the treatment of cardiogenic shock. Minerva Cardioangiol 2010;58:519­530.
Tsagalou EP, Kanakakis J, Anastasiou-Nana MI, et al.
Järvelä K, Maaranen P, Sisto T, et al.
Hemodynamic effects of levosimendan in acute myocardial Levosimendan in aortic valve surgery: cardiac performance infarction complicated by cardiogenic shock and high sys­ J Cardiothorac Vasc Anesth 2008;22:693­698.
Jörgensen K, Bech-Hanssen O, Houltz E, et al.
Cianfrocca C, Pelliccia F, Pasceri V, et al.
Effects of levosimendan on left ventricular relaxation and Strain rate analysis and levosimendan improve detection early filling at maintained preload and afterload conditions of myocardial viability by dobutamine echocardiography in after aortic valve replacement for aortic stenosis. patients with post­infarction left ventricular dysfunction: a Levin RL, Degrange MA, Porcile R, et al.
J Am Soc Echocardiogr 2008;21:1068­1074.
The calcium sensitizer levosimendan gives superior results to Fuhrmann JT, Schmeisser A, Schulze MR, et al.
dobutamine in postoperative low cardiac output syndrome. Levosimendan is superior to enoximone in refractory cardio­ genic shock complicating acute myocardial infarction. De Hert SG, Lorsomradee S, Cromheecke S, et al.
The effects of levosimendan in cardiac surgery patients Greif M, Zwermann L, Reithmann C, et al.
Levosimendan as rescue therapy in severe cardiogenic shock after ST­elevation myocardial infarction. Al-Shawaf E, Ayed A, Vislocky I, et al.
Acute Cardiac Care 2008;10:185­190.
Levosimendan or milrinone in the type 2 diabetic patient Christoph A, Prondzinsky R, Russ M, et al.
with low ejection fraction undergoing elective coronary Early and sustained haemodynamic improvement with levo­ simendan compared to intraaortic balloon counterpulsation J Cardiothorac Vasc Anesth 2006;20:353­357.
(IABP) in cardiogenic shock complicating acute myocardial Braun JP, Jasulaitis D, Moshirzadeh M, et al.
Levosimendan may improve survival in patients requiring mechanical assist devices for post­cardiotomy heart failure. Duygu H, Ozerkan F, Zoghi M, et al.
Effect of levosimendan on right ventricular systolic and Morais RJ.
diastolic functions in patients with ischaemic heart failure. Levosimendan in servere right ventricular failure following Russ MA, Prondzinsky R, Christoph A, et al.
J Cardiothorac Vasc Anesth 2006;20:82­84.
Hemodynamic improvement following levosimendan treat­ Petäjä LM, Sipponen JT, Hämmäinen PJ, et al.
ment in patients with acute myocardial infarction Levosimendan reversing low output syndrome after heart De Luca L, Sardella G, Proietti P, et al.
Lilleberg J, Nieminen MS, Akkila J, et al.
Effects of levosimendan on left ventricular diastolic function Effects of a new calcium sensitizer, levosimendan, on after primary angioplasty for acute anterior myocardial haemodynamics, coronary blood flow and myocardial infarction: a Doppler echocardiographic study. substrate utilization early after coronary artery bypass J Am Soc Echocardiogr 2006;19:172­177.
Garcia Gonzales MJ, Dominguez Rodriguez A.
Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: Potential role of levosimendan. ISCHAEMIC HEART DISEASE
Am J Cardiovasc Drugs 2006;6:69­75.
Husebye T, Eritsland J, Müller C, et al.
De Luca L, Proietti P, Celotto A, et al.
Levosimendan in acute heart failure following primary Levosimendan improves hemodynamics and coronary percutaneous coronary interventiontreated acute ST­ flow reserve after percutaneous coronary intervention in elevation myocardial infarction. Results from the LEAF trial: patients with acute myocardial infarction and left ventri­ a randomized, placebo­controlled study. Eur J Heart Fail 2013;Jan 2: [Epub ahead of print].
Qarawani D, Cohen A, Nahir M, et al.
Michaels AD, McKeown B, Kostal M, et al.
Facilitation of left ventricular function recovery post Effects of intravenous levosimendan on human coronary percutaneous coronary intervention by levosimendan. vasomotor regulation, left ventricular wall stress, and Int J Cardiol 2012;Oct 11: [Epub ahead of print].
myocardial oxygen uptake. Circulation 2005;111:1504­1509. Moiseyev VS, Pöder P, Andrejevs N, et al.
Morelli A, Teboul J-L, Maggiore SM, et al.
Safety and efficacy of a novel calcium sensitizer, levosimen­ Effects of levosimendan on right ventricular afterload in dan, in patients with left ventricular failure due to an acute patients with acute respiratory distress syndrome: myocardial infarction. A randomized, placebo­controlled, Morelli A, De Castro S, Teboul J-L, et al.
Effects of levosimendan on systemic and regional hemo­
INTENSIVE CARE/ANAESTHESIA
dynamics in septic myocardial depression. Intensive Care Med 2005;31:638­644.
Doorduin J, Sinderby CA, Beck J, et al.
The calcium sensitizer levosimendan improves human
d iaphragm function.
PAEDIATRICS
Am J Respir Crit Care Med 2012;185:90­95.
Ebade AA, Khalil MA, Mohamed AK.
Jaber S, Jung B, Matecki S, et al.
Levosimendan is superior to dobutamine as an inodilator Clinical review: Ventilator­induced diaphragmatic in the treatment of pulmonary hypertension for children dysfunction ­ human studies confirm animal model findings. J Anesth 2012;Dec 9: [Epub ahead of print].
Morelli A, Donati A, Ertmer C, et al.
Pellicer A, Riera J, Lopez-Ortego P, et al.
Levosimendan for resuscitating the microcirculation in Phase 1 study of two inodilators in neonates undergoing patients with septic shock: a randomized controlled study. Crit Care 2010;R232. [Epub ahead of print].
Pediatr Res 2012;Nov 8: [Epub ahead of print].
Morelli A, Ertmer C, Pietropaoli P, et al.
De Carolis MP, Piastra M, Bersani I, et al.
Reducing the risk of major elective non­cardiac surgery: Levosimendan in two neonates with ischemic heart failure is there a role for levosimendan in the preoperative Lechner E, Hofer A, Leitner-Peneder G, et al.
Katsaragakis S, Kapralou A, Drimousis P, et al.
Levosimendan versus milrinone in neonates and infants Prophylactic preoperative levosimendan administration in after corrective open­heart surgery: A pilot study. heart failure patients undergoing elective non­cardiac sur­ Pediatr Crit Care Med 2012;May 22 [Epub ahead of print].
gery: a preliminary report. Hellenic J Cardiol 2009;50:185­192.
Ricci Z, Garisto C, Favia I, et al.
Levosimendan infusion in newborns after corrective surgery
Meaudre E, Jego C, Goutorbe P, et al.
for congenital heart disease: randomized controlled trial. Weaning failure from mechanical ventilation due to dilated cardiomyopathy: successful use of levosimendan. Acta Anaesthesiol Scand 2009;53:416­417.
Suominen PK.
Single­center experience with levosimendan in children
Alhashemi JA, Alotaibi QA, Abdullah GM, et al.
undergoing cardiac surgery and in children with decompen­ Effects of levosimendan in acute heart failure and cardio­ Lobo Martínez P, Oulego Erroz I, Gautreux Minaya S, et al.
Pinto BB, Rehberg S, Ertmer C, et al.
Treatment of acute heart failure using levosimendan for a Role of levosimendan in sepsis and septic shock.

Source: http://www.orionpharma.no/OrionPharmaNO_Global/ATTACHMENTS_Norway/PDF-attachments/SE_NO_Referenslista_Jan2013.pdf